Obermatt
See Similar Stocks →

Glenmark Pharmaceuticals

NSI:GLENMARK · INE935A01035
PharmaceuticalsLarge

360

58
EV / EBIT39
Price / Owner Earnings7
Owner Earnings Yield23
Dividend Yield31
Price/Sales32
EV / Gross Profit67
Price/Book18
Return on Capital95
Cash Return on Capital23
Return on Equity57
EBIT Margin66
Gross Profitability89
Cash Conversion91
Owner Earnings Margin12
Sales growth6
Profit Growth62
Long-Term EPS Growth87
Reinvestment25
Price momentum81
Debt load78
Refinancing41
Debt Payback100
Liquidity58
Analyst ratings68
Opinion Changes50
Price Target Upside52
Market mood31
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Glenmark Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 3/5 components.

Profile

CountryIndia
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeNSEI
Founded1977
Employees8,964
Websiteglenmarkpharma.com
ISININE935A01035
Last UpdateApr 2, 2026
Index & Theme
CardiovascularPain ManagementDermatologyGastroenterologyCentral Nervous SystemImmunologyOncologyRespiratoryBiotechnologyHealth CarePharmaceutical

Description

Glenmark Pharmaceuticals Limited develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products. Business Segments The company has distinct business segments that contribute to its overall operations. The primary se…

Analysis

Middle-of-the-road

Glenmark Pharmaceuticals Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 96.3×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 28% a year, against analyst forecasts of 22%. The gap between price and consensus is worth watching: demanding expectations.

Growth is moderate; the safety picture is sturdy. The company scores 20/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
31
2023202420252026

All-time high

66

Jan 2025

All-time low

28

Jan 2024

Average rank

43

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
32
62
84
91
Price/Earnings
46
64
75
89
Price/Book
18
59
81
87
Dividend Yield
31
18
23
40
Value (overall)
24
59
71
87

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Glenmark Pharmaceuticals with its peers
Dr. Reddy's
NSI:DRREDDY
29
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Lupin
NSI:LUPIN
67
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Aurobindo Pharma
NSI:AUROPHARMA
60
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Alkem Laboratories
NSI:ALKEM
47
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Sun Pharmaceuticals
NSI:SUNPHARMA
55
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Torrent Pharmaceuticals
NSI:TORNTPHARM
18
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →